Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, S.

Journal of the American Society of Nephrology, Vol 3, S86-S90, Copyright © 1992 by American Society of Nephrology


REVIEWS

Antihypertensive therapy in experimental diabetes

S Anderson
Division of Nephrology and Hypertension, Oregon Health Sciences University, Portland.

Systemic hypertension is an important risk factor for the progression of diabetic glomerular disease. Recognition of this detrimental aspect has prompted intensive investigation into the mechanisms by which systemic hypertension promotes diabetic glomerulopathy, as well as into potential benefits of antihypertensive therapy. Studies in diabetic rats, both normotensive and hypertensive, have established that certain antihypertensive regimens effectively slow the development of albuminuria and glomerular sclerosis. Most consistently effective have been angiotensin-converting enzyme inhibitors, which may act to protect the kidney by several different mechanisms. Other antihypertensive regimens have been less consistent.





HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP